PT  - JOURNAL ARTICLE
AU  - Peter M. Clark
AU  - Victoria A. Ebiana
AU  - Laura Gosa
AU  - Timothy F. Cloughesy
AU  - David A. Nathanson
TI  - Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine
AID  - 10.2967/jnumed.116.181693
DP  - 2017 May 01
TA  - Journal of Nuclear Medicine
PG  - 689--696
VI  - 58
IP  - 5
4099  - http://jnm.snmjournals.org/content/58/5/689.short
4100  - http://jnm.snmjournals.org/content/58/5/689.full
SO  - J Nucl Med2017 May 01; 58
AB  - Comprehensive molecular analysis of individual tumors provides great potential for personalized cancer therapy. However, the presence of a particular genetic alteration is often insufficient to predict therapeutic efficacy. Drugs with distinct mechanisms of action can affect the biology of tumors in specific and unique ways. Therefore, assays that can measure drug-induced perturbations of defined functional tumor properties can be highly complementary to genomic analysis. PET provides the capacity to noninvasively measure the dynamics of various tumor biologic processes in vivo. Here, we review the underlying biochemical and biologic basis for a variety of PET tracers and how they may be used to better optimize cancer therapy.